Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
Clinical trial NCT06596252 · RECRUITING
Trial details
- NCT number
- NCT06596252
- Sponsor
- Dr. Falk Pharma GmbH
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-21
- Primary completion
- 2026-12-01
- Enrollment
- 308
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.